- Risk associated with R&D not always being able to deliver Commercially Successful Products
- Risk of supply chain disruptions
- Risk of Revenue Concentration
- External risks: natural disasters, political events and economic fluctuations
- Risks associated with Inadequate Cyber Security and Data Privacy Measures
- Risk associated with Inferior Product Quality
- Risk of sub-optimal product pricing
- Risk of Product Liability Litigation
- Risk associated with Non-Compliance in Financial Reporting and Disclosure, and Changes to Accounting Standards
- Risk of Non-Compliance with International Laws and Regulations
Glenmark Pharmaceuticals Limited
Greenhouse gas emissions & sustainability report data
In its 2022-04 to 2023-03 reporting, Glenmark Pharmaceuticals Limited disclosed greenhouse gas emissions of 13.3K tCO2e/year (Scope 1); 64812 tCO2e/year (Scope 2); 17506 tCO2e/year (Scope 3). By scope: Scope 1: 13.3K tCO2e/year; Scope 2: 64.8K tCO2e/year; Scope 3: 17.5K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
13.3K tCO2e/year (Scope 1); 64812 tCO2e/year (Scope 2); 17506 tCO2e/year (Scope 3)
2022-04 to 2023-03
Renewable Energy
6%
of total energy
Water Usage
485.5K KL/year
2022-04 to 2023-03
Waste
3.0K MT/year
2022-04 to 2023-03
Energy Use
496.0K GJ/year
2022-04 to 2023-03
📊 Emissions by Scope (2022-04 to 2023-03)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 13.3K tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 64.8K tCO2e/year |
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | 17.5K tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2022-04 to 2023-03 | 13.3K tCO2e/year (Scope 1); 64812 tCO2e/year (Scope 2); 17506 tCO2e/year (Scope 3) |
| 2018-04 to 2019-03 | 144.4K tCO2e/year |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Reduced carbon emission intensity by around 10% through efforts over the last three years
- 6% of total energy consumption is from renewable energy sources
- 61% of the energy requirements at both the R&D sites are met by renewable energy source (hydro-power)
- 58% of total hazardous waste disposed of in FY 2023 was co-processed
- 6 out of 10 Indian sites achieved ‘Zero Waste to Landfill’ objective
🎯 Climate & Sustainability Targets
🔜 Short-term
- Water neutral operations by 2025
📅 Medium-term
- Zero waste to landfill at all plant locations by 2027
- Reduce absolute scope 1 and 2 GHG emissions by 35% by FY 2035
- Reduce scope 3 GHG emissions intensity by 28% from various activities related to pharmaceutical products by FY 2035
🔭 Long-term
- Carbon neutral enterprise by 2030 (Scope 1 and 2 emissions)
🌱 ESG Focus Areas
Business EthicsCorporate GovernanceCybersecurity & Data PrivacyProduct Quality & SafetyHuman Capital & DevelopmentEnhancing Accessibility of MedicinesClimate ChangeTalent Attraction & RetentionHuman RightsOccupational Health & SafetySupply Chain ManagementCircular EconomyRisk ManagementCommunity DevelopmentInnovation & ResearchPromoting DiversityPolicy Advocacy